D
Crescita Therapeutics Inc.
CRRTF
$0.3901
-$0.0013-0.33%
D
Sell
11/11/2024Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D- from D on 11/11/2024 due to a substantial decline in the efficiency index, total return index and solvency index. The quick ratio declined from 2.23 to 1.61, net income declined 12.25% from -$676.7 to -$759.6, and total capital declined 5.6% from $13.32M to $12.57M.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D- from D on 11/11/2024 due to a substantial decline in the efficiency index, total return index and solvency index. The quick ratio declined from 2.23 to 1.61, net income declined 12.25% from -$676.7 to -$759.6, and total capital declined 5.6% from $13.32M to $12.57M.
D
Sell
11/13/2023Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from C- on 11/13/2023 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 512.13% from -$168.2 to -$1.03M, net income declined 356.88% from -$209.2 to -$955.8, and earnings per share declined from -$0.0103 to -$0.0469.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from C- on 11/13/2023 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 512.13% from -$168.2 to -$1.03M, net income declined 356.88% from -$209.2 to -$955.8, and earnings per share declined from -$0.0103 to -$0.0469.
C
Hold
11/1/2023Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 11/1/2023 due to a noticeable decline in the volatility index, efficiency index and total return index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 11/1/2023 due to a noticeable decline in the volatility index, efficiency index and total return index.
C
Hold
8/14/2023Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 8/14/2023 due to a major increase in the growth index, volatility index and efficiency index. Total revenue increased 12.94% from $3.4M to $3.84M, EBIT increased 3.61% from -$174.5 to -$168.2, and total capital increased 0.54% from $16.53M to $16.62M.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 8/14/2023 due to a major increase in the growth index, volatility index and efficiency index. Total revenue increased 12.94% from $3.4M to $3.84M, EBIT increased 3.61% from -$174.5 to -$168.2, and total capital increased 0.54% from $16.53M to $16.62M.
C
Hold
5/24/2023Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 5/24/2023 due to a significant decline in the growth index and total return index. EBIT declined 141.41% from $421.4 to -$174.5, earnings per share declined from $0.0426 to -$0.0099, and total revenue declined 23.41% from $4.44M to $3.4M.
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 5/24/2023 due to a significant decline in the growth index and total return index. EBIT declined 141.41% from $421.4 to -$174.5, earnings per share declined from $0.0426 to -$0.0099, and total revenue declined 23.41% from $4.44M to $3.4M.
C
Hold
3/20/2023Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 3/20/2023 due to an increase in the valuation index, volatility index and efficiency index. Net income increased 480.54% from $149.5 to $867.9, and total capital increased 6.68% from $15.73M to $16.78M.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 3/20/2023 due to an increase in the valuation index, volatility index and efficiency index. Net income increased 480.54% from $149.5 to $867.9, and total capital increased 6.68% from $15.73M to $16.78M.
C
Hold
3/15/2023Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 3/15/2023 due to a decline in the volatility index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 3/15/2023 due to a decline in the volatility index.
C
Hold
2/13/2023Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 2/13/2023 due to an increase in the volatility index and total return index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 2/13/2023 due to an increase in the volatility index and total return index.
C
Hold
1/24/2023Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C- from D+ on 1/24/2023 due to an increase in the total return index and volatility index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C- from D+ on 1/24/2023 due to an increase in the total return index and volatility index.
D
Sell
1/4/2023Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D+ from C- on 1/4/2023 due to a decline in the total return index and valuation index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D+ from C- on 1/4/2023 due to a decline in the total return index and valuation index.
C
Hold
12/20/2022Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C- from D+ on 12/20/2022 due to an increase in the volatility index and valuation index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C- from D+ on 12/20/2022 due to an increase in the volatility index and valuation index.
D
Sell
12/1/2022Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D+ from C- on 12/1/2022 due to a decline in the total return index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D+ from C- on 12/1/2022 due to a decline in the total return index.
C
Hold
11/16/2022Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C- from D on 11/16/2022 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 615.17% from -$29 to $149.4, earnings per share increased from -$0.0014 to $0.0072, and operating cash flow increased 457.1% from $62.7 to $349.3.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C- from D on 11/16/2022 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 615.17% from -$29 to $149.4, earnings per share increased from -$0.0014 to $0.0072, and operating cash flow increased 457.1% from $62.7 to $349.3.
D
Sell
7/15/2022Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 7/15/2022 due to a decline in the total return index and volatility index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 7/15/2022 due to a decline in the total return index and volatility index.
D
Sell
6/16/2022Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 6/16/2022 due to an increase in the total return index, volatility index and valuation index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 6/16/2022 due to an increase in the total return index, volatility index and valuation index.
D
Sell
5/19/2022Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 5/19/2022 due to a decline in the growth index, efficiency index and solvency index. Earnings per share declined from $0.0356 to -$0.0179, net income declined 150% from $748.4 to -$374.2, and EBIT declined 135.49% from $836.5 to -$296.9.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 5/19/2022 due to a decline in the growth index, efficiency index and solvency index. Earnings per share declined from $0.0356 to -$0.0179, net income declined 150% from $748.4 to -$374.2, and EBIT declined 135.49% from $836.5 to -$296.9.
D
Sell
4/20/2022Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 4/20/2022 due to a noticeable increase in the growth index and volatility index. EBIT increased 204.04% from -$804 to $836.5, earnings per share increased from -$0.0344 to $0.0356, and total revenue increased 152.66% from $2.38M to $6M.
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 4/20/2022 due to a noticeable increase in the growth index and volatility index. EBIT increased 204.04% from -$804 to $836.5, earnings per share increased from -$0.0344 to $0.0356, and total revenue increased 152.66% from $2.38M to $6M.
D
Sell
12/22/2021Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 12/22/2021 due to a decline in the volatility index and total return index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 12/22/2021 due to a decline in the volatility index and total return index.
D
Sell
12/7/2021Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 12/7/2021 due to an increase in the volatility index and valuation index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 12/7/2021 due to an increase in the volatility index and valuation index.
D
Sell
11/18/2021Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from C on 11/18/2021 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 23.22% from -$579.7 to -$714.3, earnings per share declined from -$0.0281 to -$0.0344, and total capital declined 4.67% from $18.63M to $17.76M.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from C on 11/18/2021 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 23.22% from -$579.7 to -$714.3, earnings per share declined from -$0.0281 to -$0.0344, and total capital declined 4.67% from $18.63M to $17.76M.
C
Hold
8/12/2021Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from D+ on 8/12/2021 due to a significant increase in the valuation index, growth index and efficiency index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from D+ on 8/12/2021 due to a significant increase in the valuation index, growth index and efficiency index.
D
Sell
5/3/2021Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D+ from C- on 5/3/2021 due to a large decline in the total return index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D+ from C- on 5/3/2021 due to a large decline in the total return index.
C
Hold
4/15/2021Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C- from D+ on 4/15/2021 due to a substantial increase in the total return index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C- from D+ on 4/15/2021 due to a substantial increase in the total return index.
D
Sell
3/25/2021Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 3/25/2021 due to a substantial increase in the efficiency index, total return index and growth index. Total capital increased 1.12% from $17.34M to $17.53M.
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 3/25/2021 due to a substantial increase in the efficiency index, total return index and growth index. Total capital increased 1.12% from $17.34M to $17.53M.
D
Sell
8/13/2020Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 8/13/2020 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.0178 to -$0.1083, net income declined 505.74% from -$367.7 to -$2.23M, and EBIT declined 229.4% from -$268.7 to -$885.1.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 8/13/2020 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from -$0.0178 to -$0.1083, net income declined 505.74% from -$367.7 to -$2.23M, and EBIT declined 229.4% from -$268.7 to -$885.1.
D
Sell
7/13/2020Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 7/13/2020 due to an increase in the valuation index and volatility index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 7/13/2020 due to an increase in the valuation index and volatility index.
D
Sell
6/15/2020Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 6/15/2020 due to a noticeable decline in the total return index and volatility index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 6/15/2020 due to a noticeable decline in the total return index and volatility index.
D
Sell
5/29/2020Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 5/29/2020 due to an increase in the efficiency index, growth index and volatility index. Operating cash flow increased 402.54% from $39.4 to $198, and EBIT increased 39.48% from -$444 to -$268.7.
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 5/29/2020 due to an increase in the efficiency index, growth index and volatility index. Operating cash flow increased 402.54% from $39.4 to $198, and EBIT increased 39.48% from -$444 to -$268.7.
D
Sell
5/15/2020Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 5/15/2020 due to a decline in the valuation index and volatility index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 5/15/2020 due to a decline in the valuation index and volatility index.
D
Sell
4/29/2020Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 4/29/2020 due to an increase in the volatility index and valuation index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 4/29/2020 due to an increase in the volatility index and valuation index.
D
Sell
4/9/2020Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 4/9/2020 due to a large decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.0029 to -$0.0176, net income declined 649.4% from $66.6 to -$365.9, and EBIT declined 222.65% from $362 to -$444.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D from D+ on 4/9/2020 due to a large decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.0029 to -$0.0176, net income declined 649.4% from $66.6 to -$365.9, and EBIT declined 222.65% from $362 to -$444.
D
Sell
3/19/2020Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D+ from C- on 3/19/2020 due to a decline in the volatility index and total return index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D+ from C- on 3/19/2020 due to a decline in the volatility index and total return index.
C
Hold
3/10/2020Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 3/10/2020 due to a decline in the total return index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 3/10/2020 due to a decline in the total return index.
C
Hold
2/24/2020Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 2/24/2020 due to an increase in the total return index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 2/24/2020 due to an increase in the total return index.
C
Hold
2/7/2020Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 2/7/2020 due to a decline in the total return index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 2/7/2020 due to a decline in the total return index.
C
Hold
1/23/2020Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 1/23/2020 due to an increase in the total return index, volatility index and valuation index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 1/23/2020 due to an increase in the total return index, volatility index and valuation index.
C
Hold
1/8/2020Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 1/8/2020 due to a decline in the total return index, growth index and valuation index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 1/8/2020 due to a decline in the total return index, growth index and valuation index.
C
Hold
12/4/2019Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 12/4/2019 due to an increase in the total return index and volatility index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 12/4/2019 due to an increase in the total return index and volatility index.
C
Hold
11/19/2019Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 11/19/2019 due to a noticeable decline in the growth index and total return index. Earnings per share declined from $0.0748 to $0.0032, EBIT declined 89.49% from $3.45M to $362, and total revenue declined 46.91% from $7M to $3.72M.
Crescita Therapeutics Inc. (CRRTF) was downgraded to C- from C on 11/19/2019 due to a noticeable decline in the growth index and total return index. Earnings per share declined from $0.0748 to $0.0032, EBIT declined 89.49% from $3.45M to $362, and total revenue declined 46.91% from $7M to $3.72M.
C
Hold
8/13/2019Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 8/13/2019 due to a noticeable increase in the growth index, total return index and valuation index. Earnings per share increased from $0.0015 to $0.0748, EBIT increased 880.7% from $351.3 to $3.45M, and total revenue increased 118.96% from $3.2M to $7M.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C from C- on 8/13/2019 due to a noticeable increase in the growth index, total return index and valuation index. Earnings per share increased from $0.0015 to $0.0748, EBIT increased 880.7% from $351.3 to $3.45M, and total revenue increased 118.96% from $3.2M to $7M.
C
Hold
6/6/2019Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C- from D+ on 6/6/2019 due to an increase in the volatility index, valuation index and total return index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C- from D+ on 6/6/2019 due to an increase in the volatility index, valuation index and total return index.
D
Sell
5/17/2019Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D+ from C- on 5/17/2019 due to a large decline in the growth index. Earnings per share declined from $0.1122 to $0.0015, EBIT declined 65.71% from $1.02M to $351.3, and total revenue declined 32.01% from $4.7M to $3.2M.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D+ from C- on 5/17/2019 due to a large decline in the growth index. Earnings per share declined from $0.1122 to $0.0015, EBIT declined 65.71% from $1.02M to $351.3, and total revenue declined 32.01% from $4.7M to $3.2M.
C
Hold
5/1/2019Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to C- from D+ on 5/1/2019 due to a noticeable increase in the total return index and volatility index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to C- from D+ on 5/1/2019 due to a noticeable increase in the total return index and volatility index.
D
Sell
3/29/2019Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 3/29/2019 due to a significant increase in the valuation index, efficiency index and growth index. Earnings per share increased from $0.0134 to $0.1122, net income increased 735.25% from $282.3 to $2.36M, and operating cash flow increased 177.64% from -$602.1 to $467.5.
Crescita Therapeutics Inc. (CRRTF) was upgraded to D+ from D on 3/29/2019 due to a significant increase in the valuation index, efficiency index and growth index. Earnings per share increased from $0.0134 to $0.1122, net income increased 735.25% from $282.3 to $2.36M, and operating cash flow increased 177.64% from -$602.1 to $467.5.
D
Sell
11/14/2018Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to D from D- on 11/14/2018 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.0244 to $0.0134, EBIT increased 131.03% from -$1.25M to $388.6, and total revenue increased 90.68% from $1.79M to $3.42M.
Crescita Therapeutics Inc. (CRRTF) was upgraded to D from D- on 11/14/2018 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.0244 to $0.0134, EBIT increased 131.03% from -$1.25M to $388.6, and total revenue increased 90.68% from $1.79M to $3.42M.
D
Sell
5/10/2018Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D- from D on 5/10/2018 due to a significant decline in the efficiency index, growth index and total return index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D- from D on 5/10/2018 due to a significant decline in the efficiency index, growth index and total return index.
D
Sell
8/16/2017Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to D from D- on 8/16/2017 due to a significant increase in the efficiency index and growth index. Total revenue increased 129.95% from $1.57M to $3.61M, EBIT increased 118.22% from -$2.3M to $418.7, and earnings per share increased from -$0.1731 to $0.0267.
Crescita Therapeutics Inc. (CRRTF) was upgraded to D from D- on 8/16/2017 due to a significant increase in the efficiency index and growth index. Total revenue increased 129.95% from $1.57M to $3.61M, EBIT increased 118.22% from -$2.3M to $418.7, and earnings per share increased from -$0.1731 to $0.0267.
D
Sell
7/20/2017Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D- from D on 7/20/2017 due to a decline in the volatility index and total return index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D- from D on 7/20/2017 due to a decline in the volatility index and total return index.
D
Sell
7/5/2017Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to D from D- on 7/5/2017 due to an increase in the total return index and volatility index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to D from D- on 7/5/2017 due to an increase in the total return index and volatility index.
D
Sell
6/2/2017Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to D- from D on 6/2/2017 due to a significant decline in the efficiency index, solvency index and total return index. The quick ratio declined from 1.56 to 0.9, debt to equity increased from 0.33 to 0.37, and total capital declined 8.99% from $24.69M to $22.48M.
Crescita Therapeutics Inc. (CRRTF) was downgraded to D- from D on 6/2/2017 due to a significant decline in the efficiency index, solvency index and total return index. The quick ratio declined from 1.56 to 0.9, debt to equity increased from 0.33 to 0.37, and total capital declined 8.99% from $24.69M to $22.48M.
D
Sell
5/1/2017Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to D from D- on 05/01/2017.
Crescita Therapeutics Inc. (CRRTF) was upgraded to D from D- on 05/01/2017.
D
Sell
1/3/2017Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to D- from E on 1/3/2017 due to an increase in the valuation index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to D- from E on 1/3/2017 due to an increase in the valuation index.
E
Sell
12/7/2016Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to E from E+ on 12/7/2016 due to a significant decline in the volatility index, solvency index and total return index. The quick ratio declined from 8.97 to 2.41.
Crescita Therapeutics Inc. (CRRTF) was downgraded to E from E+ on 12/7/2016 due to a significant decline in the volatility index, solvency index and total return index. The quick ratio declined from 8.97 to 2.41.
E
Sell
10/3/2016Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to E+ from E on 10/3/2016 due to a substantial increase in the volatility index and total return index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to E+ from E on 10/3/2016 due to a substantial increase in the volatility index and total return index.
E
Sell
8/23/2016Upgraded
Crescita Therapeutics Inc. (CRRTF) was upgraded to E from E- on 8/23/2016 due to an increase in the volatility index.
Crescita Therapeutics Inc. (CRRTF) was upgraded to E from E- on 8/23/2016 due to an increase in the volatility index.
E
Sell
8/8/2016Downgrade
Crescita Therapeutics Inc. (CRRTF) was downgraded to E- from E on 8/8/2016 due to a decline in the volatility index and total return index.
Crescita Therapeutics Inc. (CRRTF) was downgraded to E- from E on 8/8/2016 due to a decline in the volatility index and total return index.
E
Sell
8/5/2016None
Crescita Therapeutics Inc. (CRRTF) was downgraded to E from U on 08/05/2016.
Crescita Therapeutics Inc. (CRRTF) was downgraded to E from U on 08/05/2016.
OTC PK
02/18/2025 10:03AM Eastern
Quotes delayed
